| Name | YF-2 |
| Description | YF-2 is blood-brain-barrier permeable histone acetyltransferase activator, acetylates H3 in the hippocampus, CBP, PCAF, and GCN5 with EC50s of 2.75 μM, 29.04 μM and 49.31 μM , respectively |
| In vitro | YF-2 (0.03, 0.1, 0.25, 0.5, 1, 2.5, 5, 15, 40 and 80 μM, 72 hours) inhibits the preliferation of U251, CCRF-CEM, Hs578T, NCI-ADR-RES cells, respectively. |
| In vivo | YF-2, administered intraperitoneally at doses of 20 mg/kg (2 hours before an electric shock) or 5 mg/kg (30 minutes prior to the electric shock), effectively rescues the defect in contextual memory in mice. At a dosage of 20 mg/kg without the electric shock treatment, YF-2 exhibits no impact on contextual memory in mice. |
| Storage | Keep away from moisture | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | H2O : Insoluble DMSO : 125 mg/mL (290.12 mM), Sonication is recommended. 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 4 mg/mL (9.28 mM), Sonication is recommended.
|
| Keywords | YF-2 | YF2 | YF 2 | PCAF | Inhibitor | inhibit | HistoneAcetyltransferase | Histone Acetyltransferase | HATs | HAT | GCN5 | EpigeneticReaderDomain | Epigenetic Reader Domain | CBP |
| Inhibitors Related | ABBV-744 | SNDX-5613 | 3-methyl-1,2,3,4-tetrahydroquinazolin-2-one | (+)-JQ-1 | Acetaminophen | 5-Ph-IAA | Manganese chloride (tetrahydrate) | Curcumin | N4-Acetylcytidine | Naphthol AS-E | JQ-1 (carboxylic acid) | Bisdemethoxycurcumin |
| Related Compound Libraries | Histone Modification Compound Library | Anti-Neurodegenerative Disease Compound Library | Bioactive Compound Library | Epigenetics Compound Library | CNS-Penetrant Compound Library | Anti-Cardiovascular Disease Compound Library | Stem Cell Differentiation Compound Library | Bioactive Compounds Library Max | Fluorochemical Library | Anti-Cancer Compound Library | Anti-Cancer Active Compound Library | Anti-Hypertension Compound Library |